In this article SOLS Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:23 02:23 Honeywell CEO: The power of AI is going to redefine automation Mad Money with Jim Cramer Honeywell CEO Vimal Kapur told CNBC's Jim Cramer that AI is creating a major growth opportunity for the industrial conglomerate's next chapter. "The power of AI is going to redefine automation," Kapur said on " Mad ...
In this article SOLS Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:23 02:23 Honeywell CEO: The power of AI is going to redefine automation Mad Money with Jim Cramer Honeywell CEO Vimal Kapur told CNBC's Jim Cramer that AI is creating a major growth opportunity for the industrial conglomerate's next chapter. "The power of AI is going to redefine automation," Kapur said on " Mad Money " on Thursday. His comments come as Honeywell prepares to spin off its aerospace business on June 29, leaving behind a pure-play automation company . Honeywell's automation business provides sensors, controls and software that help customers manage critical operations across hospitals, airports, data centers, semiconductor facilities and liquefied natural gas plants. Cramer's Charitable Trust , the portfolio used by the CNBC Investing Club, owns shares of Honeywell. Last fall, Honeywell spun off Solstice Advanced Materials , continuing its multiyear effort to simplify the portfolio and concentrate on its automation businesses. "We are taking the opportunity to build a pure play automation company across multiple sectors, and opportunity is more compelling now, with AI coming in," Kapur said. Kapur said AI makes those systems more valuable because they already generate enormous amounts of operational data that can now become actionable optimization insights, improve decision-making and automate tasks that previously required human intervention. The need for those tools is growing as businesses struggle to find enough skilled workers, according to Kapur. Honeywell's customers are facing shortages of operators and technicians across sectors, he said, while aging populations and slowing workforce growth are likely to make the problem worse over time. "Net workforce is not going to be increasing. It's going to be decreasing over a period of time," Kapur said. As a result, companies are increasingly turning to AI and automation to do more with fewer people. However, Kapur s...
Brand Industrial Services Inc. , a scaffolding and industrial services company that does business as BrandSafway, reported sharply lower first-quarter earnings as higher costs and spending on its push into data center construction weighed on results, according to people familiar with the matter. The company, controlled by private equity firm Clayton, Dubilier & Rice , reported a 20% year-over-year...
Brand Industrial Services Inc. , a scaffolding and industrial services company that does business as BrandSafway, reported sharply lower first-quarter earnings as higher costs and spending on its push into data center construction weighed on results, according to people familiar with the matter. The company, controlled by private equity firm Clayton, Dubilier & Rice , reported a 20% year-over-year decline in earnings before interest, taxes, depreciation and amortization, according to the people, who declined to be named because the results are private. That earnings measure fell to $71 million, one of the people said. The Atlanta-based company said the weaker results reflected higher costs and spending tied to its recent expansion into data center construction, the people said. The company’s loans and bonds have fallen from above 90 cents on the dollar since December. Its $1.5 billion term loan dropped about 2 points on Monday to 79.625, according to data compiled by Bloomberg, after the company released earnings last Friday. BrandSafway serves customers in oil and gas, power generation, civil infrastructure and commercial construction, according to its website. Its results add to signs that higher costs are pressuring construction and industrial companies. Representatives of BrandSafway and Clayton, Dubilier & Rice did not return calls seeking comment. On a call with debt holders earlier this week, the company said it expects its full-year 2026 profit to come in slightly above last year’s level as it passes higher costs on to customers through the rest of the year, according to one of the people. The company has also been spending heavily on its expansion into data center construction, the people said. It used more cash than expected, according to one of the people and a Jefferies analyst report earlier this week. Jefferies representatives also did not respond to a request for comment.
Apple (AAPL) stock is at an interesting point right now. It has strong momentum, and if you bet on it, you are betting on a company with strong margin, good cash flow, low-debt capital structure, and good tailwinds. But is that enough.
Apple (AAPL) stock is at an interesting point right now. It has strong momentum, and if you bet on it, you are betting on a company with strong margin, good cash flow, low-debt capital structure, and good tailwinds. But is that enough.
Justin Sullivan/Getty Images News In my last article on Adobe Inc. ( ADBE ), my rating was a Buy. It has been almost a year, and during this period the stock has fallen 34%. I think it is fair to say that I was partially wrong, or at least that it was an analysis that was “too early,” I do not think I was completely wrong, precisely because the tone of the article was quite cautious, mentioning th...
Justin Sullivan/Getty Images News In my last article on Adobe Inc. ( ADBE ), my rating was a Buy. It has been almost a year, and during this period the stock has fallen 34%. I think it is fair to say that I was partially wrong, or at least that it was an analysis that was “too early,” I do not think I was completely wrong, precisely because the tone of the article was quite cautious, mentioning that I did not believe a high re-rating was very likely, and that AI could indeed be a long-term risk to Adobe's thesis. If that decline was not enough, ADBE stock is down 6% in the after-hours, and in my view, that makes the Adobe case even more asymmetric. Adobe's Q2 Earnings: Quietly strong Looking purely at the financials, Adobe's results were excellent. A beat on the main estimates and also a raise in guidance. Both revenue and adj. EPS for the quarter were a beat of ~2.5%. As for FY 2026, after the guidance raise, revenue is 2% above what the market was expecting, and EPS is 3.8% above consensus, using the high end of guidance . Seeking Alpha In other words, the financials were quite solid, and show that at least so far, Adobe is managing to deliver compounding in the top line. Note below that quarter after quarter Adobe continued delivering revenue growth, and more importantly, is maintaining annual recurring revenue growth close to low double digits. Adobe Data Sheet That alone might be enough to remove part of the market's perception that Adobe is a dying company. After all, what dying company can maintain so many consecutive quarters of ARR growth at this pace and still accelerate, delivering 12.5% in Q2? But unfortunately, reality is not that simple. Part of the Q2 ARR was inflated by the Semrush acquisition, which added $480 million. If we remove this effect, ARR growth goes from ~12.5% to something closer to 10%. Even more important than that are the expectations. Adobe mentioned that it is adopting a new strategy, sacrificing ARR to increase the number of monthl...
MicroStockHub/iStock via Getty Images Investment Thesis This is my first time providing coverage of Monte Rosa Therapeutics, Inc. ( GLUE ), a Boston based biotech specializing in the development of a class of drugs known as molecular glue degraders ("MGDs"). As the company puts it in its Q1 2026 quarterly report / 10-Q filing : MGDs are small molecule drugs that employ the body’s natural protein d...
MicroStockHub/iStock via Getty Images Investment Thesis This is my first time providing coverage of Monte Rosa Therapeutics, Inc. ( GLUE ), a Boston based biotech specializing in the development of a class of drugs known as molecular glue degraders ("MGDs"). As the company puts it in its Q1 2026 quarterly report / 10-Q filing : MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. MGDs work by inducing the engagement of defined surfaces identified on target proteins by an E3 ligase, such as cereblon. We have developed a proprietary and industry-leading protein degradation discovery engine, called QuEENTM to enable our unique, and target-centric, MGD discovery and development and our rational design of MGD products. Protein degrader technology is being been developed by the likes of Kymera Therapeutics ( KYMR ), Arvinas ( ARVN ), and C4 Therapeutics ( CCCC ) and others, alongside several large Pharma companies, although only a handful of drugs with this mechanism of action ("MoA") have been approved to date. It is now recognized that lenalidomide and pomalidomide, marketed and sold as Revlimid and Pomalyst by Bristol-Myers Squibb Company ( BMY ) and indicated for multiple myeloma, are types of protein degrader drugs, as is the selective estrogen receptor degrader elacestrant, approved last January to treat breast cancer as Orserdu, and marketed and sold by Italian drugmaker Menarini, fulvestrant, another breast cancer drug marketed and sold by AstraZeneca ( AZN ) under the brand name Faslodex, and most recently Inluriyo (imlunestrant), developed by Eli Lilly ( LLY ), and also indicated for breast cancer. Monte Rosa completed its initial public offering ("IPO") in June 2021, raising ~$222m at $19 per share. At the time of writing, its stock trades at $16.8 per share, and its market cap valuation is $1.42bn. Stock is in fact up >220% on a 1-year basis. Its pipeline is illust...